- PureTech affiliate Sonde Health announced it had completed a $16m Series A financing round to advance Sonde's vocal biomarker technology.

The proceeds from the financing would be used to progress the firm's capability across multiple health conditions and device types and to fund commercialisation activities.

The round was led by M Ventures, the corporate venture capital arm of Merck KGaA, with participation from MP Healthcare Venture Management, Neoteny 4, LP, Canepa Healthcare and founder PureTech Health.

Sonde's proprietary technology is designed to enable a range of consumer devices, such as smartphones and smart speakers, to provide disease screening and management solutions based on acoustic analysis of seconds of voice, measuring a variety of metrics imperceptible to most listeners.

"Sonde is pioneering an entirely new approach to health care with its proprietary platform. Their technology is designed to efficiently detect early signs of illness and monitor for changes in health using just a few seconds of voice. It's an exciting approach with the potential to improve treatments and outcomes across a wide range of diseases," said Eric Elenko, Chief Innovation Officer at PureTech Health.

At 9:47am: [LON:PRTC] PureTech Health Plc share price was +5.75p at 171.5p

Story provided by